CIELO · WN43174
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A Phase III multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of satralizumab in patients with anti-N-methyl-D-aspartate receptor (NMDAR) or leucine-rich glioma-inactivated 1 (LGI1) encephalitis. EudraCT: 2023-504226-18-00
Sponsor: ROCHE
Phase: III
Area: Epilepsy